[
  {
    "objectID": "cv.html",
    "href": "cv.html",
    "title": "Resume",
    "section": "",
    "text": "Medicine Degree\nUniversity of Santiago de Compostela, Spain\n10/2002-7/2008\nBachelor’s Degree in Computer Engineering\nOpen University of Catalonia, Spain\n1/2016-1/2023\nPh.D. in Medicine\nExcellent Cum Laude and extraordinary doctorate award\nAutonomous University of Barcelona, Spain\n10/2011-11/2014\nPh.D. in Bioinformatics\nExcellent Cum Laude and extraordinary doctorate award\nOpen University of Catalonia, Spain\n6/2018-12/2020\nInternal Medicine Residency\nVall d’Hebron University Hospital, Barcelona, Spain\n5/2009-5/2014\nInflammatory Muscle Diseases Clinical Fellowship\nMuscle Disease Unit, NIAMS/NIH\nBethesda, United States of America\n7/2018-1/2021\nMaster of Research Methodology in Health Sciences\nAutonomous University of Barcelona, Spain\n11/2011-4/2015\nMaster of Advanced Studies in Molecular Medicine\nUniversity of Santiago de Compostela, Spain\n7/2008-9/2010"
  },
  {
    "objectID": "cv.html#original-research",
    "href": "cv.html#original-research",
    "title": "Resume",
    "section": "Original research",
    "text": "Original research\n\nPinal-Fernandez I*, Munoz-Braceras S*, Casal-Dominguez M, et al. Pathological autoantibody internalisation in myositis. Ann Rheum Dis 2024.\nBurbelo P, Huapaya JA, Khavandgar Z, Beach M, Pinal-Fernandez I, et al. Quantification of Autoantibodies Using a Luminescent Profiling Method in Autoimmune Interstitial Lung Diseases. Frontiers in Immunology 2024.\nNajjar R, Alessi H, Pinal-Fernandez I, et al. Distinct transcript-level expression profiles and unique alternative splicing in inflammatory myopathies. ACR Open Rheumatology 2024.\nAbad C, Pinal-Fernandez I, Guillou C, et al. IFN\\(\\gamma\\) causes mitochondrial dysfunction and oxidative stress in myositis. Nature Communications 2024\nFernandez-Codina A, Nevskaya T, Baron M, …, Pinal-Fernandez I, Janet E Pope. Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial. Rheumatology 2024.\nTorres-Ruiz J*, Pinal-Fernandez I*, Selva-O’Callaghan A*, Cambpell B*, et al. Nailfold capillaroscopy findings of a multicentric multiethnic cohort of patients with idiopathic inflammatory myopathies. Clin Exp Rheum 2024.\nSherman MA, Noroozi Farhadi P, Pak K, et al. Myositis-associated autoantibodies in juvenile myositis are associated with refractory disease and mortality. Arthritis and Rheumatology 2024. As a member of the Childhood Myositis Heterogeneity Collaborative Study Group.\nNath A, Walitt B, …, Pinal-Fernandez I, et al. Deep phenotyping of Post-infectious Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Nature Communications 2024.\nKleefeld F, Horvath R, Pinal-Fernandez I, et al. Multi-level profiling unravels mitochondrial dysfunction in Myotonic Dystrophy type 2. Acta Neuropathologica 2023.\nSherman M, Yang Q, Gutierrez-Alamillo L, et al. Clinical features and immunogenetic risk factors associated with additional autoantibodies in anti-TIF1\\(\\gamma\\) juvenile-onset dermatomyositis. Arthritis and Rheumatology 2023. As a member of the Childhood Myositis Heterogeneity Collaborative Study Group.\nMuñoz-Braceras S, Pinal-Fernandez I, Casal-Dominguez M, et al. Identification of unique microRNA profiles in different types of idiopathic inflammatory myopathy. Cells 2023.\nLopez-Guerra N*, Matas-Garcia A*, …, Pinal-Fernandez I#, Milisenda JC#. Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature. Autoimmun Rev 2023.\nPinal-Fernandez I*, Milisenda JC*, Pak K*, Munoz-Braceras S*, et al. Transcriptional derepression of CHD4/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies. Ann Rheum Dis 2023.\nSherman MA, Pak K, Pinal-Fernandez I, et al. Anti-Sp4 autoantibodies co-occur with anti-TIF1 and are associated with distinct clinical features and immunogenetic risk factors in juvenile myositis. Arthritis Rheumatol 2023.\nPinal-Fernandez I*, Quintana A*, Milisenda JC*, Casal-Dominguez M*, et al. Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor-induced myositis. Ann Rheum Dis 2023.\nNascimiento A, Bruels CC, Donkervoort S, …, Pinal-Fernandez I, et al. Variants in DTNA cause a mild, dominantly inherited muscular dystrophy. Acta Neuropathologica 2023.\nCasal-Dominguez M*, Pinal-Fernandez*, Pak K, et al. Coordinated local RNA overexpression of complement induced by interferon gamma in myositis. Scientific Reports 2023.\nMilisenda JC*, Pinal-Fernandez I*, Lloyd T, et al. The Pattern of MHC Class I Expression in Muscle Biopsies from Patients with Myositis and other Neuromuscular Disorders. Rheumatology 2023.\nMammen AL, Amato AA, Dimachkie MM, Chinoy H, Hussain Y, Lilleker JB, Pinal-Fernandez I, et al. Zilucoplan in immune-mediated necrotizing myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial. Lancet Rheumatology 2022.\nMichelle EH*, Pinal-Fernandez I*, Casal-Dominguez M*, et al. Clinical subgroups and factors associated with progression in patients with inclusion body myositis. Neurology 2023.\nHosono Y*, Sie B*, Pinal-Fernandez I*, Pak K*, et al. Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in dermatomyositis patients with anti-TIF1\\(\\gamma\\) autoantibodies. Ann Rheum Dis 2023.\nSherman MA, Graf R, Sabbagh SE, Galindo-Feria AS, Pinal-Fernandez I, et al. Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not severe disease features. Rheumatology 2022.\nLehky T, Pinal-Fernandez I, Krakow EF, et al. Neuropathy and Muscle Cramps in Autologous and Allogeneic Hematopoietic Cell Transplantation Survivors. Cell Ther Transplant 2022.\nCuvelier GDE, Schoettler M, Buxbaum N, Pinal-Fernandez I, et al. Towards a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. Transplantation and Cellular Therapy 2022.\nIkenaga C, Date H, Kanagawa M, Mitsui J, Ishiura H, Yoshimura J, Pinal-Fernandez I, et al. Muscle transcriptomics shows overexpression of CDH1 in inclusion body myositis. Ann Neurol 2022.\nTrallero-Araguas E, Gil-Vila A, Martinez-Gomez X, Pinal-Fernandez I, et al. Cancer screening in idiopathic inflammatory myopathies: ten years experience from a single center. Semin Arthritis Rheum 2022.\nBritson K, Ling JP, Braunstein K, Montagne JM, Kastenschmidt JM, Wilson A, Ikenaga C, Tsao W, Pinal-Fernandez I, et al. Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Sci Transl Med 2021.\nAmici DR, Pinal-Fernandez I, Christopher-Stine L, Mammen AL, Mendillo ML. A network of core and subtype-specific gene expression programs in myositis. Acta Neuropathol 2021.\nCasal-Dominguez M*, Pinal-Fernandez I*, Pak K, Huang W, Selva-O’Callaghan A, et al. Performance of the 2017 EULAR/ACR classification criteria for inflammatory myopathies in patients with myositis-specific autoantibodies. Arthritis Rheumatol 2021.\nPinal-Fernandez I*, Pak K*, Gil-Vila A*, Baucells A*, Plotz B*, et al. Anti-cortactin autoantibodies are associated with key clinical features in adult myositis but are rarely present in juvenile myositis. Arthritis Rheumatol 2021.\nSempere-González A, Llaneras-Artigues, Pinal-Fernandez I, et al. Radiography-based triage for COVID-19 in the Emergency Department in a Spanish cohort of patients. Med Clin (Barc) 2021.\nCasal-Dominguez M, Pinal-Fernandez I, Derfoul A, et al. The phenotype of myositis patients with anti-Ku autoantibodies. Seminars in Arthritis and Rheumatism 2021.\nSabbagh SE*, Pinal-Fernandez I*, Casal-Dominguez M, et al. Anti-mitochondrial autoantibodies are associated with cardiomyopathy, dysphagia, and features of more severe disease in adult-onset myositis. Clinical Rheumatology 2021.\nOrozco-Galvez O, Fernandez-Codina A, Pinal-Fernandez I, Martinez-Valle F, Simo-Perdigo M. Response to treatment in IgG4-related disease assessed by quantitative positron emission tomography-computerized tomography scan. Clinical Nuclear Medicine 2020.\nMontagne JM, Zheng XA, Pinal-Fernandez I, et al. Ultra-Efficient Short Read Sequencing of Immune Receptor Repertoires. EBioMedicine 2020.\nSabbagh S, Neely J, Chow A, DeGuzman M, Lai J, Lvovich S, McGrath T, Pereira M, Pinal-Fernandez I, et al. Risk factors associated with Pneumocystis jirovecii pneumonia in juvenile myositis in North America. Rheumatology (Oxford) 2020.\nPinal-Fernandez I, Casal-Dominguez M, Derfoul A, et al. Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. Ann Rheum Dis 2020;79:1234-42.\nCasal-Dominguez M*, Pinal-Fernandez I*, Pak K, et al. The indirect immunofluorescence assay autoantibody profiles of myositis patients without known myositis-specific autoantibodies. Clin Exp Rheum 2020.\nMilisenda JC*, Pinal-Fernandez I*, Lloyd T, et al. Accumulation of autophagosome cargo protein p62 is common in idiopathic inflammatory myopathies. Clin Exp Rheum 2020.\nFernandez-Codina A, Pinilla B, Pinal-Fernandez I, et al. Performance of the 2019 ACR/EULAR classification criteria for IgG4-RD and clinical phenotypes in a Spanish multicenter registry (REERIGG4). Rheumatology (Oxford) 2020.\nRomero-Bueno F, Diaz del Campo P, Trallero-Araguás E, Ruiz-Rodríguez JC, Castellvi I, Rodriguez-Nieto MJ, Martínez-Becerra MJ, Sanchez-Pernaute O, Pinal-Fernandez I, et al. Recommendations for the Treatment of Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. Semin Arthritis Rheum 2020;50:776-90.\nSeto N, Torres-Ruiz JJ, Carmona-Rivera C, Pinal-Fernandez I, et al. Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. JCI Insight 2020;5.\nParks C*, Pak K*, Pinal-Fernandez I*, et al. Trim33 (Tif1\\(\\gamma\\)) is not required for skeletal muscle development or regeneration but suppresses cholecystokinin expression. Sci Rep 2019;9:18507.\nMecoli CA, Albayda J, Tiniakou E, Paik JJ, Zahid U, Danoff SK, Casciola-Rosen L, Casal-Dominguez M, Pak K, Pinal-Fernandez I, et al. Myositis Autoantibodies: A Comparison of Results from the Oklahoma Medical Research Foundation Myositis Panel to the Euroimmun Research Line Blot. Arthritis Rheumatol 2020;72:192-4.\nMilisenda JC, Garcia AM, Jou C, Pinal-Fernandez I, et al. Sporadic inclusion body myositis: Diagnostic value of p62 immunostaining. Med Clin (Barc) 2019;153:437-40.\nHuapaya J, Silhan L, Pinal-Fernandez I, et al. Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease. Chest 2019;156:896-906.\nPinal-Fernandez I*, Mecoli C*, Casal-Dominguez M*, et al. More prominent muscle involvement in those dermatomyositis patients with anti-Mi2 autoantibodies. Neurology 2019;93:e1768-e77.\nHuapaya JA, Hallowell R, Silhan L, Pinal-Fernandez I, et al. Long-term treatment with human Immunoglobulin for antisynthetase syndrome-associated interstitial lung disease. Respir Med 2019;154:6-11.\nPinal-Fernandez I*, Pak K*, Casal-Dominguez M*, Hosono Y, Mecoli C, Christopher-Stine L, Mammen AL. Validation of anti-Mi2 autoantibody testing by line blot. Autoimmun Rev 2020;19:102425.\nPinal-Fernandez I, Casal-Dominguez M, Derfoul A, et al. Identification of distinctive interferon gene signatures in different types of myositis. Neurology 2019;93:e1193-e204.\nSabbagh S*, Pinal-Fernandez I*, Kishi T, et al. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis 2019;78:988-95.\nCasal-Dominguez M*, Pinal-Fernandez I*, Huapaya J, et al. Efficacy and adverse effects of methotrexate compared with azathioprine in the Antisynthetase Syndrome. Clin Exp Rheumatol 2019;37:858-61.\nPinal-Fernandez I*, Amici DR*, Parks CA, Derfoul A, et al. Myositis autoantigen expression correlates with muscle regeneration but not autoantibody specificity. Arthritis Rheumatol 2019;71:1371-6.\nBrusca RM, Pinal-Fernandez I, Psoter K, et al. The ILD-GAP Risk Prediction Model Performs Poorly in Myositis-Associated Interstitial Lung Disease. Respir Med. 2019;150:63-5.\nRandazzo D, Khalique U, Belanto J, Kenea A, Talsness DM, Olthoff JTJ, Tran MD, Zaal KJ, Pak K, Pinal-Fernandez I, et al. Persistent upregulation of the \\(\\beta\\)-tubulin tubb6, linked to muscle regeneration, is a source of microtubule disorganization in dystrophic muscle. Hum Mol Genet. 2019;28(7):1117-35.\nMilisenda JC*, Collado MV*, Pinal-Fernandez I*, et al. Correlation between quantitative and semiquantitative magnetic resonance imaging and histopathology findings in dermatomyositis. Clin Exp Rheumatol 2019;37:633-40.\nCasal-Dominguez M*, Pinal-Fernandez I*, Corse A, et al. Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies. Neurology. 2019;92(13):e1416-e26.\nAmici DR*, Pinal-Fernandez I*, Pagkatipunan R, et al. Muscle endurance deficits in myositis patients despite normal manual muscle testing scores. Muscle Nerve. 2019;59(1):70-5.\nDe Lorenzo R*, Pinal-Fernandez I*, Huang W, et al. Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies. Neurology. 2018;90(23):e2068-e76.\nFernandez-Codina A, Pinilla B, Pinal-Fernandez I, et al. Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index. Joint Bone Spine. 2018;85(6):721-6.\nYeker RM*, Pinal-Fernandez I*, Kishi T, et al. Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. Ann Rheum Dis. 2018;77(5):714-9.\nRedondo-Benito A, Curran A, Villar-Gomez A, Trallero-Araguas E, Fernandez-Codina A, Pinal-Fernandez I, Rodrigo-Pendas JA, Selva-O’Callaghan A. Opportunistic infections in patients with idiopathic inflammatory myopathies. Int J Rheum Dis. 2018;21:487-96.\nPinal-Fernandez I, Ferrer-Fabregas B, Trallero-Araguas E, Balada E, Martinez MA, Milisenda JC, et al. Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. Rheumatology (Oxford). 2018;57:388-96.\nSuarez-Calvet X, Gallardo E, Pinal-Fernandez I, et al. RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis. Arthritis Res Ther. 2017;19(1):174.\nPinal-Fernandez I*, Casal-Dominguez M*, Huapaya JA*, et al. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology (Oxford). 2017;56(6):999-1007.\nAmici DR, Pinal-Fernandez I, Mazala DA, et al. Calcium dysregulation, functional calpainopathy, and endoplasmic reticulum stress in sporadic inclusion body myositis. Acta Neuropathol Commun. 2017;5(1):24.\nFernandez-Codina A, Berastegui C, Pinal-Fernandez I, et al. Lung transplantation in systemic sclerosis: A single center cohort study. Joint Bone Spine. 2018;85(1):79-84.\nLloyd TE, Pinal-Fernandez I, Michelle EH, et al. Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. Neurology. 2017;88(15):1454-60.\nCasal-Dominguez M*, Pinal-Fernandez I*, Mego M, et al. High-resolution manometry in patients with idiopathic inflammatory myopathy: Elevated prevalence of esophageal involvement and differences according to autoantibody status and clinical subset. Muscle Nerve. 2017;56:386-92.\nEscola-Verge L, Pinal-Fernandez I, Fernandez-Codina A, et al. Mixed Connective Tissue Disease and Epitope Spreading: An Historical Cohort Study. J Clin Rheumatol. 2017;23(3):155-9.\nAlbayda J*, Pinal-Fernandez I*, Huang W, et al. Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients. Arthritis Care Res (Hoboken). 2017;69:1771-6.\nTiniakou E*, Pinal-Fernandez I*, Lloyd TE, et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology (Oxford). 2017;56(5):787-94.\nPinal-Fernandez I*, Casal-Dominguez M*, Carrino JA, et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis. 2016;76(4):681-7.\nAlvarado-Cardenas M, Marin-Sanchez A, Martinez MA, Martinez-Martinez L, Pinal-Fernandez I, Labrador-Horrillo M, et al. Statin-associated autoimmune myopathy: A distinct new IFL pattern can increase the rate of HMGCR antibody detection by clinical laboratories. Autoimmun Rev. 2016;15(12):1161-6.\nMartinez-Valle F, Fernandez-Codina A, Pinal-Fernandez I, Orozco-Galvez O, Vilardell-Tarres M. IgG4-related disease: Evidence from six recent cohorts. Autoimmunity Reviews. 2017;16(2):168-72.\nBasharat P, Lahouti AH, Paik JJ, Albayda J, Pinal-Fernandez I, Bichile T, Lloyd TE, Danoff SK, Casciola-Rosen L, Mammen AL, Christopher-Stine L. Statin-Induced Anti-HMGCR-Associated Myopathy. J Am Coll Cardiol. 2016;68(2):234-5.\nJohnson C, Pinal-Fernandez I, Parikh R, et al. Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease. Lung. 2016;194(5):733-7.\nPinal-Fernandez I*, Parks C*, Werner JL, et al. Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle. Arthritis Care Res (Hoboken). 2017;69(2):263-70.\nPinal-Fernandez I, Pineda-Sanchez V, Pallisa-Nunez E, et al. Fast 1.5 T chest MRI for the assessment of interstitial lung disease extent secondary to systemic sclerosis. Clinical Rheumatology. 2016(9);35:2339-45.\nLloyd TE, Christopher-Stine L, Pinal-Fernandez I, et al. Cytosolic 5’-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. Arthritis Care Res (Hoboken). 2016;68(1):66-71.\nFernandez-Codina A, Simeon-Aznar CP, Pinal-Fernandez I, et al. Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival. Rheumatol Int. 2017;37(1):75-84.\nPinal-Fernandez I, Pallisa-Nunez E, Selva-O’Callaghan A, et al. Pleural irregularity, a new ultrasound sign for the study of interstitial lung disease in systemic sclerosis and antisynthetase syndrome. Clin Exp Rheumatol. 2015;33:S136-41.\nPinal-Fernandez I, Casciola-Rosen LA, Christopher-Stine L, Corse AM, Mammen AL. The Prevalence of Individual Histopathologic Features Varies according to Autoantibody Status in Muscle Biopsies from Patients with Dermatomyositis. J Rheumatol. 2015;42(8):1448-54.\nPinal Fernandez I, Pallisa Nunez E, Selva-O’Callaghan A, Castella-Fierro E, Martinez-Gomez X, Vilardell-Tarres M. Correlation of ultrasound B-lines with high-resolution computed tomography in antisynthetase syndrome. Clin Exp Rheumatol. 2014;32(3):404-7.\nPinal-Fernandez I, Selva-O’Callaghan A, Fernandez-Codina A, et al. \"Pregnancy in adult-onset idiopathic inflammatory myopathy\": report from a cohort of myositis patients from a single center. Semin Arthritis Rheum. 2014;44(2):234-40.\nArmadans-Tremolosa I, Selva-O’Callaghan A, Visauta-Vinacua B, Guilera G, Pinal-Fernandez I, Vilardell-Tarres M. Health-related quality of life and well-being in adults with idiopathic inflammatory myopathy. Clin Rheumatol. 2014; 33(8):1119-25.\nPinal-Fernandez I, Martin-Pastor M, Ferro-Gallego P, Dominguez-Gerpe L. Ex vivo proton NMR analysis and characterization of thymus lipid metabolites and their variation with age in C57BL/6 mice. Curr Aging Sci. 2011;4(1):57-69."
  },
  {
    "objectID": "cv.html#review-articles",
    "href": "cv.html#review-articles",
    "title": "Resume",
    "section": "Review articles",
    "text": "Review articles\n\nSelva-O’Callaghan A, Trallero-Araguas E, Gil-Vila A, …, Pinal-Fernandez I. Treatment and Monitoring of eosinophilic Fasciitis. Current Treatment Options in Rheumatology 2024.\nMusai J, Mammen AL, and Pinal-Fernandez I. Recent Updates on the Pathogenesis of Inflammatory Myopathies. Curr Rheumatol Rep 2024.\nBeecher G, Pinal-Fernandez I, Mammen AL, et al. Immune Checkpoint Inhibitor Myopathy: The Double-Edged Sword of Cance Immunotherapy. Neurology 2024.\nJammal C, Pinal-Fernandez I, Mammen AL. Adult inflammatory myopathies: updates on classification and management. Practica Neurology 2024.\nSevim E., Kobrin D, Casal-Dominguez M, Pinal-Fernandez I. Comprehensive Review of Dermatomyositis Treatments - From Rediscovered Classics to Promising Horizons. Expert Review of Clinical Immunology 2023.\nSelva-O’Callaghan A, Guillen-del-Castillo A, …, Pinal-Fernandez I, Simeon-Aznar C. Systemic Sclerosis-Associated Myopathy: How to Treat. Current Treatment Options in Rheumatology 2023.\nOgbonnaya-Whittlesey SA, Kobrin D, Casal-Dominguez M, Mammen AL Pinal-Fernandez I. Treatment of Immune-Mediated Necrotizing Myopathy. Current Treatment Options in Rheumatology 2023.\nCasal-Dominguez M, Pinal-Fernandez I, Mammen AL. Utility of Myositis-Specific Autoantibodies for Treatment Selection in Myositis. Current Treatment Options in Rheumatology 2022.\nCasal-Dominguez M*, Pinal-Fernandez I*, Mammen AL. Inhibitin interferon pathways in dermatomyositis: rationale and preliminary evidence. Current Treatment Options in Rheumatology 2021.\nSelva-O’Callaghan A, Romero-Bueno F, Trallero-Araguas E, Gil-Vila A Ruiz-Rodriguez JC, Sanchez-Pernaute O, Pinal-Fernandez I. Pharmacologic treatment of anti-MDA5 rapidly progressive interstitial lung disease. Current Treatment Options i Rheumatology 2021.\nSelva-O’Callaghan A, Gil-Vila A, Simó-Perdigó M, Trallero-Araguás E Alvarado-Cárdenas M, Pinal-Fernandez I. PET Scan: Nuclear Medicine Imaging in Myositis. Curr Rheumatol Rep 2019;21:64.\nSelva-O’Callaghan A, Gil-Vila A, Trallero-Araguás E Pinal-Fernandez I. Malignancy and Myositis, from Molecular Mimicry to Tumor Infiltrating Lymphocytes. Neuromuscul Disor 2019;29:819-25.\nSelva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguas E Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurolog 2018;17:816-28.\nPinal-Fernandez I, Mammen AL. Dermatomyositis etiopathogenesis: A rebel soldier in the muscle. Curr Opin Rheumatol 2018;30:623-9.\nSelva-O’Callaghan A, Martinez-Gomez X, Trallero-Araguas E, Pinal-Fernandez I. The diagnostic work-up of cancer-associated myositis. Curr Opin Rheumatol. 2018;30(6):630-6.\nPinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-Mediated Necrotizing Myopathy. Curr Rheumatol Rep. 2018;20(4):21.\nSelva-O’Callaghan A, Alvarado-Cardenas M, Pinal-Fernandez I, et al. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol. 2018:1-10.\nPinal-Fernandez I, Casal-Dominguez M, Mammen AL. Statins: pros and cons. Med Clin (Barc). 2018;150:398-402.\nCasal-Dominguez M, Pinal-Fernandez I, Selva-O’Callaghan A. Protocol for dyspnea in inflammatory myopathies. Medicine. 2017;12(29):1729-34.\nPinal-Fernandez I, Mammen AL. Spectrum of immune-mediated necrotizing myopathies and their treatments. Curr Opin Rheumatol. 2016;28(6):619-24.\nSelva-O’Callaghan A, Trallero-Araguas E, Martinez MA, Labrador-Horrillo M, Pinal-Fernandez I, Grau-Junyent JM, et al. Inflammatory myopathy: diagnosis and clinical course, specific clinical scenarios and new complementary tools. Expert Rev Clin Immunol. 2015;11(6):737-47.\nSelva-O’Callaghan A, Alvarado-Cardenas M, Marin A, Pinal-Fernandez I. Statins and myositis: the role of anti-HMGCR antibodies. Expert Rev Clin Immunol. 2015;11(12):1277-9.\nCasal Domínguez M, Pinal-Fernandez I. [Guidelines for type 2 diabetes mellitus]. Archivos de Medicina. 2014;10(2);1-18.\nPinal-Fernandez I, Selva-O’Callaghan A, Grau JM. Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev. 2014;13(4-5):379-82."
  },
  {
    "objectID": "cv.html#case-reports",
    "href": "cv.html#case-reports",
    "title": "Resume",
    "section": "Case reports",
    "text": "Case reports\n\nPinal-Fernandez I, Kroodsma CT, Mammen AL. Successful treatment of refractory mechanic’s hands with ustekinumab in a patient with the antisynthetase syndrome. Rheumatology (Oxford) 2019;58:1307-8.\nPinal-Fernandez I, Fonollosa-Pla V, Selva-O’Callaghan A. Improvement of the nailfold capillaroscopy after immunosuppressive treatment in polymyositis. QJM. 2016;109(3):205-6.\nPinal-Fernandez I, Garrigasait Vilaseca V, Fernandez-Codina A, Aranda Rodriguez S. [Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome]. Medicina (B Aires). 2014;74(6):474-5.\nPinal-Fernandez I, Callejas-Moraga EL, Roade-Tato ML, Simeon-Aznar CP. Groove sign in eosinophilic fasciitis. Lancet. 2014;384(9956):1774.\nCallejas Moraga EL, Pinal Fernandez I, Roade Tato L, Santafe Colomina M. [Littoral cell angioma. An uncommon cause of constitutional syndrome]. Med Clin (Barc). 2015;144(5):239.\nPinal-Fernandez I, Solans-Laque R. The ‘sparing phenomenon’ of purpuric rash over tattooed skin. Dermatology. 2014;228(1):27-30.\nPinal-Fernandez I, Miranda-Barrio B. Giant aortic aneurysm in Marfan syndrome. QJM. 2014;107(2):155.\nPinal Fernandez I, Moris Felgueroso M, Trallero Araguas E. [Lanthanum carbonate abdominal foreign bodies]. Med Clin (Barc). 2014;142(9):426.\nFernandez-Codina A, Aleman C, Simon-Talero M, Salcedo-Allende MT, Pinal-Fernandez I, Segura-Garcia A. Sarcoidosis with complications. Intern Emerg Med. 2014;9(7):817-8.\nPinal-Fernandez I, Ferrer Fabrega B, Ramentol Sintas M, Solans Laque R. Histiocytoid Sweet syndrome and cutaneous polyarteritis nodosa secondary to myelodysplastic syndrome. Int J Rheum Dis. 2013;16(6):777-9.\nPinal Fernandez I, Borras A, Mejia E. [Chest pain of 48 hours of evolution in a 41 years-old man]. Med Clin (Barc). 2013;141(9):390-6.\nAndres Cordon JF, Pinal Fernandez I, Willekens Morales R, Arderiu Freixa MA. [Recurrent pleural effusion and marked elevation of CA-125 in a patient with pseudo-Meigs’ syndrome secondary to a struma ovarii]. Med Clin (Barc). 2013;140(5):237.\nPortela M, Pinal L, Olga S, Dalama B. Diabetes insipidus as an atypical presentation of acute myeloid leukemia. Endocrinol Nutr. 2012;59(8):516-7.\nPinal Fernandez I, Segura Garcia A. [Intrapulmonary solitary fibrous tumor]. Med Clin (Barc). 2012;139(6):276.\nPinal-Fernandez I, Segura-Garcia A. [Tolvaptan in antidiuretic hormone secretion syndrome secondary to treatment with citalopram]. Rev Clin Esp. 2011;211(9):491-2.\nPinal Fernandez I, Molina Romero I, Sulleiro Igual E, Segura Garcia A. [Massive eosinophilia and cholestatic hepatitis due to Strongyloides stercoralis infection]. Rev Clin Esp. 2011;211(6):e34-6.\nPinal-Fernandez I. [Humoral hypercalcemia in mixed endometrial carcinoma]. An Sist Sanit Navar. 2010;33(2):217-9."
  },
  {
    "objectID": "cv.html#editorials",
    "href": "cv.html#editorials",
    "title": "Resume",
    "section": "Editorials",
    "text": "Editorials\n\nPinal-Fernandez I, Greenberg S. Type I Interferons in Dermatomyositis Myoblasts: Toxic Effect and a Potential Autocrine Loop. Neurology 2022.\nPinal-Fernandez I, Mammen AL. Amyloid-PET: a new tool for diagnosing IBM. Nat Rev Rheumatol 2019;15:321-2."
  },
  {
    "objectID": "cv.html#letters-correspondence",
    "href": "cv.html#letters-correspondence",
    "title": "Resume",
    "section": "Letters, correspondence",
    "text": "Letters, correspondence\n\nFernandez-Codina A, Nevskaya T, Baron M, …, Pinal-Fernandez I, Janet E Pope. Brentuximab vedotin compared to historical controls for severe skin involvement in cutaneous systemic sclerosis. Rheumatology 2024.\nJohnson C, Schiffenbauer AI, Perin J, et al. HLA Alleles Associated with Interstitial Lung Disease in North Americans with Idiopathic Inflammatory Myopathy. Am J Respir Crit Care Med 2022. As a member of the Myositis-ILD Study Group.\nMammen A, Pinal-Fernandez I, Rider L. Conflicting reports of anti-NT5C1a autoantibodies in juvenile myositis: Comment on the article by Rietveld et al. Arthritis Rheumatol 2021.\nPinal-Fernandez I, Mammen AL. Myositis-specific autoantibodies as relevant adjusting variables in myositis research. Correspondence to “From diagnosis to prognosis: Revisiting the meaning of muscle ISG15 overexpression in juvenile inflammatory myopathies” by Hou et al. Arthritis Rheumatol 2021.\nPinal-Fernandez I, Casal-Dominguez M, Milisenda JC, Mammen AL. Response to: Correspondence on ‘Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis’ by Takanashi et al. Ann Rheum Dis 2021.\nPinal-Fernandez I, Mammen AL. Case 22-2019: A 65-Year-Old Woman with Myopathy. N Engl J Med 2019;381:1693-4.\nPinal-Fernandez I, Mammen AL. On using machine learning algorithms to define clinically meaningful patient subgroups. Ann Rheum Dis 2019.\nPinal-Fernandez I, Pak K, Huang W, Mammen AL. Reply to: Myocarditis in Patients With Antisynthetase Syndrome: Prevalence, Presentation, and Outcomes. Medicine (Baltimore) 2015.\nSelva-O’Callaghan A, Labirua-Iturburu A, Pinal-Fernandez I. Antisynthetase Antibodies in World Trade Center Rescue and Recovery Workers With Inflammatory Myositis: Comment on the Article by Webber et al. Arthritis Rheumatol. 2015;67:2791."
  },
  {
    "objectID": "cv.html#book-chapters",
    "href": "cv.html#book-chapters",
    "title": "Resume",
    "section": "Book chapters",
    "text": "Book chapters\n\nSelva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, Gil-Vila A. Chapter 37: Eosinophilic fasciitis. Autoimmune Disease Diagnosis. Systemic and Organ-specific Diseases. 2nd ed: Springer Nature Switzerland; 2025:271-275.\nSelva-O’Callaghan A, Trallero-Araguás E, Pinal Fernandez I. Chapter 25: Cancer-Associated Myositis. Managing Myositis. A Practical Guide. Springer Nature Switzerland; 2020.\nCasal-Dominguez M, Pinal Fernandez I, A Selva-O´Callaghan. [Chapter 3: Myositis and the lung. Antisynthetase autoantibodies syndrome]. [Advances in inflammatory myopathies]. 1st ed: Marge Books; 2017.\nSelva O’Callaghan A, Pinal Fernandez I. [Chapter 13: Journal choice] In: Jimenez Villa J, Amartin Zurro A, Argimon Pallas JM, Vilardell Tarres M, eds. [Biomedical scientific publication]. 2nd ed: Elsevier; 2015:213-22.\nPinal Fernandez I, Casal Dominguez M. [Non-biological immunosuppresive drugs] In: CreateSpace, ed. Wikimecum. 1st ed: Internet Medical Publishing; 2015.\nCasal Dominguez M, Pinal Fernandez I. [Guidelines for type 2 diabetes mellitus]. 1st ed: Internet Medical Publishing; 2015.\nPinal Fernandez I. [Pulmonary embolism] In: CreateSpace, ed. AEMIR emergencies guidebook. 3th ed: Internet Medical Publishing; 2012.\n\n*Co-first authors\n#Co-last authors"
  },
  {
    "objectID": "contact.html",
    "href": "contact.html",
    "title": "Contact",
    "section": "",
    "text": "E-mail: iago.pinal@gmail.com\nniams.gov | Google Scholar | ResearchGate\nTwitter | LinkedIn | GitHub\n\n\n\n Back to top"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Iago Pinal-Fernandez",
    "section": "",
    "text": "Iago Pinal-Fernandez, M.D., Ph.D., Ph.D., is a Staff Clinician in the Muscle Disease Unit of the NIAMS/NIH. He joined in 2015 as a Visiting Fellow, then transitioned to a Clinical Fellowship before becoming a Staff Clinician in 2021. Dr. Pinal-Fernandez is also an Adjunct Assistant Professor in the Department of Neurology at Johns Hopkins University School of Medicine and an Assistant Professor in the Faculty of Computer Science, Multimedia and Telecommunications at the Open University of Catalonia.\nDr. Pinal-Fernandez graduated from the Santiago de Compostela School of Medicine and completed his 5-year Internal Medicine residency in the Vall d’Hebron hospital in Barcelona. He has two doctoral degrees, the first in medicine and the second in bioinformatics, two master’s degrees, one in molecular medicine and the other in research methodology, as well as a bachelor’s degree in computer engineering."
  },
  {
    "objectID": "index.html#summary",
    "href": "index.html#summary",
    "title": "Iago Pinal-Fernandez",
    "section": "",
    "text": "Iago Pinal-Fernandez, M.D., Ph.D., Ph.D., is a Staff Clinician in the Muscle Disease Unit of the NIAMS/NIH. He joined in 2015 as a Visiting Fellow, then transitioned to a Clinical Fellowship before becoming a Staff Clinician in 2021. Dr. Pinal-Fernandez is also an Adjunct Assistant Professor in the Department of Neurology at Johns Hopkins University School of Medicine and an Assistant Professor in the Faculty of Computer Science, Multimedia and Telecommunications at the Open University of Catalonia.\nDr. Pinal-Fernandez graduated from the Santiago de Compostela School of Medicine and completed his 5-year Internal Medicine residency in the Vall d’Hebron hospital in Barcelona. He has two doctoral degrees, the first in medicine and the second in bioinformatics, two master’s degrees, one in molecular medicine and the other in research methodology, as well as a bachelor’s degree in computer engineering."
  },
  {
    "objectID": "index.html#research-statement",
    "href": "index.html#research-statement",
    "title": "Iago Pinal-Fernandez",
    "section": "Research Statement",
    "text": "Research Statement\nDr. Pinal-Fernandez’s research is focused on understanding the pathogenesis of inflammatory muscle diseases and on improving the diagnosis, prognosis, and treatment of patients with these conditions. To do so, he combines a variety of modalities of clinical and translational research. From a clinical perspective, he is involved in several natural history studies, and clinical trials to test novel treatments in patients with different types of myositis. Translationally, he is using bioinformatics and data science to understand inflammatory myositis by combining clinical, epidemiological, and molecular data."
  }
]